Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
Israel's Lumenis is bucking the hesitance of many medical device companies to pursue the public markets and is moving ahead with its IPO plans. The maker of minimally invasive medical lasers released further details in a recent regulatory filing, noting that it wants to sell 6.3 million shares and raise approximately $100 million.
Amedica has priced its public offering, and in doing so has lowered expectations for the second time this week. The Utah medical device company said it will roll out of the gate with an offering of 3.5 million shares of common stock at $5.75 per share, a price much lower than the company initially proposed.
Diagnostics wunderkind Foundation Medicine has made its way to the Nasdaq, hauling in a $106 million IPO at the top of its range.
Put lightly, it was less than a banner year for medical device and diagnostics companies looking to go public. Check out the report >>
Cancer Genetics will ramp up clinical trials plus expand its sales and marketing staff with an initial public offering the company envisions will haul in close to $49 million.
Australia seems to be an increasingly popular spot for foreign devicemakers to raise funds through initial public offerings and subsequently list on that country's exchange. Following in the footsteps of GI Dynamics, U.S.-based Osprey Medical has raised $20 million Australian in its IPO and plans to list on the Australian Securities Exchange.
Globus Medical made a splash Thursday by filing with the SEC to raise up to $100 million in an initial public offering.
Seattle's Atossa Genetics, which offers diagnostic tests to detect precursors to breast cancer, is planning an initial public offering of 1 million shares of its common stock. In a filing with the
Lexington, MA-based GI Dynamics has raised about $85 million from its Australian IPO. The company said it would list Sept. 7 in Sydney with a market value of AU$304 million ($324.6 million), The